Ankylosing Spondylitis

Latest News

Radiographic Sacroiliitis vs MRI Structural Lesions for Axial Spondyloarthritis Classification

Radiographic Sacroiliitis vs MRI Structural Lesions for Axial Spondyloarthritis Classification

Researchers sought to investigate the utility of adding structural MRI lesions of the sacroiliac joints to the imaging criterion of the ASAS axSpA criteria.

Sustained Clinical, Functional Improvements With Adalimumab in Axial Spondyloarthritis

Sustained Clinical, Functional Improvements With Adalimumab in Axial Spondyloarthritis

Results from the ABILITY-1 study show sustained clinical and functional improvements with adalimumab treatment in nonradiographic axial spondyloarthritis.

Biosimilar Etanercept SB4 May Decrease Disease Activity in Inflammatory Rheumatic Disease

Biosimilar Etanercept SB4 May Decrease Disease Activity in Inflammatory Rheumatic Disease

Nonmandatory transitioning from originator etanercept to biosimilar etanercept SB4 using a specifically designed communication strategy showed a slightly lower persistence rate and smaller decreases in disease activity.

Disease Activity in Axial Spondyloarthritis Generally Low, Stable During Pregnancy

Disease Activity in Axial Spondyloarthritis Generally Low, Stable During Pregnancy

Researchers found that disease activity was highest during the second trimester of pregnancy.

Trabecular Bone Score May Predict Future Vertebral Fracture in Axial Spondyloarthritis

Trabecular Bone Score May Predict Future Vertebral Fracture in Axial Spondyloarthritis

Researchers found that trabecular bone scores may be predictive of future vertebral fractures in patients with axial spondyloarthritis.

TNF Inhibitors Reduce Long-Term Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis

TNF Inhibitors Reduce Long-Term Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis

TNFi therapy yielded favorable results in patients with AS or PsA, with progressively better responses between 4 months and 3 years.

FDA Label Update for Certolizumab Pegol Affects Women of Childbearing Age

FDA Label Update for Certolizumab Pegol Affects Women of Childbearing Age

The FDA has approved a label update to include pharmacokinetic data showing low transfer of certolizumab pegol through placenta and minimal transfer to breast milk from mother to infant.

Comorbid Fibromyalgia and Axial Spondyloarthritis: Response to TNF Blocker Therapy

Comorbid Fibromyalgia and Axial Spondyloarthritis: Response to TNF Blocker Therapy

Researchers sought to confirm whether concomitant fibromyalgia has a negative effect on TNF blocker response.

Adalimumab Reduces Whole-Body MRI Indices of Inflammation in axSpA

Adalimumab Reduces Whole-Body MRI Indices of Inflammation in axSpA

Adalimumab may decrease whole-body magnetic resonance imaging indices of inflammation in both axial and peripheral joints and enthuses in axSpA.

Anti-CD74 Antibodies Have Limited Diagnostic Value in Early Axial Spondyloarthritis

Anti-CD74 Antibodies Have Limited Diagnostic Value in Early Axial Spondyloarthritis

Anti-CD74 IgG and IgA antibodies have limited value in the diagnosis of early axial spondyloarthritis in younger patients who present with early back pain.

Sign Up for Free e-newsletters